Autopsy report · NCT06068153

AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC

Cause of deathOther Automatic label, confidence 0.5, unverified. How labels are made.

“In view of the recent developments in the field (the increasing number of trials with new KRAS inhibitors), the window of opportunity to answer the question raised in the AMBER trial was missed.”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 2
Sponsor: ETOP IBCSG Partners Foundation
Sponsor type: University, hospital or other
Conditions: Metastatic Non Small Cell Lung Cancer; KRAS G12C
Interventions: Sotorasib; Lenvatinib
Participants: 0
Sites: 15
Countries: Austria, Germany, Spain, Switzerland

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.